Oasis Pharmaceuticals, LLC, is a privately funded start-up consisting of a team of experienced entrepreneurs, exceptional scientists, regulatory specialists, and physicians committed to advancing therapeutic treatment for NASH, IPF, and AD/pruritus.

We use pepducin chemistry to develop and commercialize novel therapeutics that uniquely target the critical intracellular domains of cell surface receptors.  Our proprietary cell-penetrating PAR2 pepducin technology will advance a new generation of drugs to effectively treat inflammatory and fibrotic diseases.

Screen Shot 2019-04-11 at 10.49.51 AM.pn